Sargent Investment Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 24,701 shares of the company's stock after purchasing an additional 3,692 shares during the period. Sargent Investment Group LLC's holdings in Johnson & Johnson were worth $4,096,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Shares of Johnson & Johnson stock traded up $0.67 during trading hours on Friday, reaching $163.65. The company's stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,141,137. The firm has a 50 day moving average price of $154.29 and a 200-day moving average price of $155.05. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market cap of $393.75 billion, a P/E ratio of 17.50, a P/E/G ratio of 2.08 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the firm posted $2.82 EPS. The business's quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.
Wall Street Analyst Weigh In
JNJ has been the subject of a number of recent research reports. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday. Guggenheim lifted their target price on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a research note on Thursday. Finally, Raymond James Financial lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $172.87.
Read Our Latest Analysis on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More

Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.